MIAMI, FL USA (UroToday.com) - The efficacy of fesoterodine was assessed in patients with refractory OAB symptoms after treatment for BPH. This was a single-center pilot study of 18 male patients > 40 years of age who had bladder outlet obstruction, treated surgically, at least one month prior.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Primary endpoint was a change in International Prostate Symptom Score (IPSS) with secondary endpoints maximum urine flow rates and PVR. Fesoterodine significantly improved IPSS compared to baseline. Adverse events were: 3 (17%) patients had constipation, 1 (6%) with vision change, and 2 (11%) with dry mouth.
Presented by Lily C. Wang, Bilal Chughtai, Asha E. Jamzadeh, Richard K. Lee, Steven A. Kaplan, and Alexis E. Te at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Winter Meeting - February 25 - March 1, 2014 - Doral Golf Resort and Spa - Miami, Florida USA
Reported for UroToday.com by Diane K. Newman, DNP, FAAN, BCB-PMD